相关临床试验
470
78 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1827
进行中（未招募）
17
3.6%
已完成
233
49.6%
Enrolling By Invitation
3
0.6%
尚未招募
58
12.3%
招募中
50
10.6%
终止
11
2.3%
Unknown
93
19.8%
撤回
5
1.1%
暂无批准数据
- An Ontario-wide study published in BMJ identified 24 potentially inappropriate prescribing cascades that are common in the population and carry potential for harm. - Prescribing cascades occur when a drug's side effect is mistaken for a new condition, prompting an unnecessary additional prescription, such as NSAID-induced blood pressure rises treated with antihypertensives. - Researchers screened 65 previously defined cascades against ICES population prescription data using three measures: initial drug frequency, likelihood of a follow-on prescription, and strength of the link. - The authors point to automated clinical decision support and expanded pharmacist involvement as strategies to flag cascades at the point of care.
- Canada announced the hiring of 64 scholars supported by more than C$500 million ($350 million) over eight years through its Global Impact+ Research Talent Initiative. - Forty-eight of the recruited academics come from US institutions including Harvard, Cornell, and MIT, spanning medicine, engineering, and climate science. - Researchers cited frozen federal grants and concerns over academic freedom under the Trump administration as key factors driving their departure. - The initiative is part of a C$1.7 billion ($1.2 billion) effort to attract world-leading researchers to Canadian universities.
- University of Toronto researchers engineered transfer RNA (tRNA) to suppress disease-causing nonsense mutations and restore full-length protein production across laboratory and preclinical models of cystic fibrosis. - A single chemical modification, N1-methyladenosine (m1A), increased suppressor tRNA readthrough activity by about 10.6-fold and extended its apparent half-life from roughly 12 to 29 days. - A custom lipid nanoparticle, TTP-3, delivered the tRNA to key airway cells, and combining the therapy with Trikafta restored CFTR function in patient-derived organoids. - Because nonsense mutations arise from only three premature stop signals shared across many genes, the platform could eventually treat multiple genetic diseases with one therapeutic strategy.
- A 12-week randomized trial of 74 adults with overweight or obesity found three daily servings of full-fat dairy caused no meaningful changes in body weight, body composition, or cholesterol compared with a low-dairy diet. - Participants consuming full-fat dairy showed lower blood pressure and higher intake of calcium, protein, and vitamin D, with no evidence of increased insulin resistance or adverse blood lipid levels. - Researchers attribute the findings to the "dairy matrix hypothesis," which proposes that dairy's physical structure slows nutrient delivery and alters the effects of its saturated fat. - The results challenge long-standing low-fat dairy guidance, though experts caution the study did not directly compare full-fat versus low-fat dairy and may have been too short to detect longer-term effects.
- Toronto researchers developed CRISPR-KOALA, a dual-function gene-editing tool that can simultaneously silence and activate genes within living mouse models to mimic chromosomal chaos. - Screening over 3,700 genes identified 81 previously unrecognized cancer-driving genes in basal-like breast cancer, with 90% going undetected in standard cell culture experiments. - The gene PLGRKT emerged as a potent driver, helping cancer cells survive in oxygen-deprived tumor regions by switching metabolic processes, making it a compelling therapeutic target. - Basal-like breast cancer, also called triple-negative breast cancer, disproportionately affects younger women of color and has some of the worst outcomes due to a lack of known genetic drivers and targeted therapies.
- University of Toronto and McMaster University are anchoring a new $40-million life sciences venture capital fund managed by Genesys Capital, with a first close of over $30 million already secured. - The fund will invest up to $1 million each in 10 to 15 seed-stage startups focused on medical devices and drugs targeting cancer, heart, and brain ailments, primarily from the two universities. - The Ontario government, through Venture Ontario, is contributing up to $10 million, with U of T committing up to $8 million and McMaster $5 million from technology transfer revenues. - The initiative aims to address Canada's chronic early-stage funding gap that has historically driven promising life sciences innovators to relocate to Boston or Silicon Valley.
- A population-based study of 55,606 Ontario patients found female TBI patients were 26% less likely to be admitted to specialized trauma centres than males, even after adjusting for age, injury severity, and comorbidities. - Female patients were older (median age 78 vs. 67), more often injured by low-energy falls, and had lower rates of severe head trauma (25% vs. 33%) compared to males. - Researchers suggest unconscious sex-related bias and lower prehospital priority for low-energy mechanisms may contribute to the disparity in triage and admission. - The authors call for further investigation into sex- and gender-based variability in trauma triage to guide targeted interventions and reduce disparities.
- A new AI tool developed by University of Toronto and Mayo Clinic researchers can classify meningioma molecular groups from routine H&E pathology slides with up to 97% accuracy. - The deep learning models provide prognostic information in under an hour using only a laptop, eliminating the need for costly and time-consuming DNA methylation profiling. - The study, published in The Lancet Digital Health, analyzed tissue samples from over 600 patients and demonstrated AI-based recurrence predictions remained useful beyond traditional clinical factors. - Researchers have made the models publicly available as a decision support tool while prospective validation studies for wider clinical use are ongoing.
- Long-term exposure to fine particulate matter and nitrogen dioxide at levels below current regulatory limits is associated with advanced coronary artery disease, according to a study of over 11,000 adults in Toronto. - Women showed significantly greater odds of serious artery narrowing with higher pollution exposure, while the association in men was not statistically significant. - A separate review of 95 global studies found that 67% showed significant links between low-level PM2.5 exposure and cardiovascular harm, with vulnerable populations at heightened risk. - Researchers suggest that stricter air quality standards could meaningfully protect cardiovascular health, as no clear "safe" threshold was identified.
- NinaMED Pty Ltd, a newly formed Australian medical device company, secured $13.75 million in financing led by SPRIM Global Investments to develop the NiNA System®, a non-invasive, at-home therapy for overactive bladder. - The NiNA System® targets the saphenous nerve through wearable neuromodulation technology, offering a drug-free alternative for the estimated 550 million people worldwide affected by overactive bladder. - The company obtained exclusive global licensing rights from Toronto-based EBT Medical and appointed Ian Meredith, former Boston Scientific executive, as Board Chair to lead commercialization efforts. - The financing will accelerate clinical development, support an Investigational Device Exemption application, and build operations in Australia for worldwide commercialization of this novel therapeutic approach.
